There is clinical evidence that anti-EGFR rechallenge can work in mCRC, even after prior progression. That said, this case isn't a ''pure'' rechallenge. FT836 has enhanced ADCC capacity and direct CAR-mediated killing. So the observed reductions could more likely be a combination effect rather than cetuximab alone.
Market Data 
Markets 
AI
